NYSE:CHE - Chemed Stock Price, Forecast & News

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed announced a quarterly dividend on Friday, February 21st. Shareholders of record on Monday, March 2nd will be given a dividend of $0.32 per share on Monday, March 23rd. This represents a $1.28 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Friday, February 28th. View Chemed's Dividend History.

Chemed declared that its board has initiated a share buyback program on Wednesday, March 7th 2018, which allows the company to buyback $150,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its shares are undervalued.

Chemed Co. (NYSE:CHE) announced its earnings results on Tuesday, February, 18th. The company reported $4.22 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.13. The firm had revenue of $522.30 million for the quarter, compared to analyst estimates of $524.20 million. Chemed had a return on equity of 35.38% and a net margin of 11.35%. Chemed's revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company posted $3.35 earnings per share. View Chemed's Earnings History.

Chemed is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Chemed.

Chemed updated its FY20 earnings guidance on Tuesday, February, 18th. The company provided earnings per share (EPS) guidance of $16.20-16.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.63.

4 analysts have issued 12-month target prices for Chemed's stock. Their forecasts range from $405.00 to $535.00. On average, they anticipate Chemed's share price to reach $482.50 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Price Targets for Chemed.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chemed.

News coverage about CHE stock has been trending very negative on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chemed earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Chemed.

Chemed saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 188,400 shares, a decline of 10.2% from the January 30th total of 209,700 shares. Based on an average daily trading volume, of 74,600 shares, the short-interest ratio is currently 2.5 days. Approximately 1.2% of the shares of the company are short sold. View Chemed's Current Options Chain.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include Home Depot (HD), Altria Group (MO), AbbVie (ABBV), AT&T (T), CVS Health (CVS), Chevron (CVX), Walt Disney (DIS), Enterprise Products Partners (EPD), Occidental Petroleum (OXY) and Boeing (BA).

Chemed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.26%), FMR LLC (2.83%), State Street Corp (2.49%), Riverbridge Partners LLC (2.29%), Investec Asset Management LTD (1.70%) and Geode Capital Management LLC (1.28%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Institutional Ownership Trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Russell Investments Group Ltd., Barclays PLC, State Street Corp, Goldman Sachs Group Inc., Prudential Financial Inc., State of Tennessee Treasury Department and Smith Asset Management Group LP. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Spencer S Lee and Walter L Krebs. View Insider Buying and Selling for Chemed.

CHE stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Teacher Retirement System of Texas, Loomis Sayles & Co. L P, Marshall Wace North America L.P., Investec Asset Management LTD, Thrivent Financial for Lutherans and Bank of America Corp DE. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders and George J Walsh III. View Insider Buying and Selling for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $417.62.

Chemed has a market capitalization of $6.71 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 15,707 workers across the globe.View Additional Information About Chemed.

The official website for Chemed is http://www.chemed.com/.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202-4726. The company can be reached via phone at 513-762-6690.